Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO

PRINCETON, N.J., May 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) is scheduled to host a webcast review of the ipilimumab data presented during the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. As previously announced, the live webcast will begin...

Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma

Conference call scheduled for tomorrow, Tuesday, December 11, 2007 at 8:45 am ET PRINCETON, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) and Bristol-Myers Squibb Company (NYSE: BMY ) today announced top-line data from the three registra...

Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab

PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) and Bristol-Myers Squibb Company (NYSE: BMY ) today announced that, after meeting with the U.S. Food and Drug Administration (FDA), the companies will delay the Biologics License Application (BLA) submission fo...

Promising Therapy for Prostate Cancer

...ng surgery] asked if we were sending him samples from the same patient." ipilimumab is an antibody that appears to greatly magnify the cancer-killing action of... therapy in the same news release. The team plans more research into how ipilimumab works and how to optimize its use. More information The American Ca...

Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City

...rom Medarex's oncology portfolio included the following: ipilimumab is a fully human anti-CTLA-4 antibody in development for melanoma, prostate...s. Risks and uncertainties include risks associated with the development of ipilimumab and other product candidates, uncertainties related to the outcome of clini...

Medarex Announces 2008 Fourth Quarter and Year End Financial Results

...ear ended December 31, 2008, decreased by $4.4 million from $20.4 million in 2007 to $16.0 million in 2008 and relates primarily to the development of ipilimumab with Bristol-Myers Squibb Company. Research and development (R&D) expenses for the year ended December 31, 2008, decreased by $3.4 millio...

A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn a Higher Patient Share in the U.S. Than in Europe

... ipilimumab Will Earn Decision Resources' Clinical Gold Standa...aders indicate that Bristol-Myers Squibb/Medarex's ipilimumab has advantages over dacarbazine in the attribute o...Following its approval in 2010 for the indication, ipilimumab will earn Decision Resources' proprietary clinical...

Medarex Reviews Recent Highlights and Outlook for 2009

...rex's continual investment in its pipeline and the net contributions to the ipilimumab program. Medarex expects its monthly cash burn rate per month for the full ...s. Risks and uncertainties include risks associated with the development of ipilimumab and other product candidates, uncertainties related to the outcome of clini...

The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016

...four new MAbs by 2016: Genmab/GlaxoSmithKline's ofatumumab for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, Medarex/Bristol-Myers Squibb's ipilimumab for malignant myeloma, Genmab's zanolimumab for T-cell lymphoma, and Genentech/Roche/Chugai's pertuzumab for breast cancer. "These emerging MAbs wil...

OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer

...he body from immune overreactions, but when it is expressed in the presence of mutant cancer cells the result is tumor evasion of the immune response. ipilimumab is an antibody that blocks CTLA-4, releasing this safety brake, and allowing the immune response to have a stronger anti-tumor effect. ...

Ipilimumab in Medical Technology

Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting

PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced interim results from a Phase 1/2 trial of ipilimumab, an investigational oncology immunotherapy, as monotherapy or in combination with radiotherapy in patients with metastatic castration resistant ...

Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today interim results from two ongoing Phase 1 trials in hormone refractory prostate cancer (HRPC) demonstrating dose-dependent T-cell activation and clinical activity of ipilimumab, an investigational...

Medarex Announces Ipilimumab Program Continues to Move Forward

Previously-Stated Guidance Remains Unchanged PRINCETON, N.J., April 3, 2008 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today issued the following statement in response to the announcement by Pfizer Inc that it was discontinuing its Phase 3 clinical trial of front-li...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

Clinical Phase I and II data presented at American Society of Clinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc. and Bristol-Myers Squibb Company today presented results from multiple clinical studies of ipilimumab (MDX-010), an investigatio...

Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology

... Updated Survival Data for ipilimumab to be Presented PRINCETON, N.J., Sept. 4 /PRNews...ated patients with advanced metastatic melanoma: ipilimumab Presentations in Advanced Melanoma -- "Efficacy ...ay, September 13, 2008. -- "Clinical activity of ipilimumab in patients with advanced melanoma and brain metas...

Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City

... cash burn rate of approximately $14.5 million. This guidance includes Medarex's continual investment in its pipeline and the net contributions to the ipilimumab program. Also for the full year of 2008, Medarex expects projected revenues to be in the range of $48 to $52 million; R&D expense in the range of $1...

Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma

...a Phase 2 clinical study (MDX010-08) of 3 mg/kg of ipilimumab in combination with dacarbazine (DTIC) where 11.4%....4 years). The median OS for patients treated with ipilimumab in combination with DTIC was 15 months in this stu...9022) "The long-term survival data suggests that ipilimumab in combination with DTIC may have long-lasting eff...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

...e following clinical and preclinical abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as... Survival, Response, Safety and Biomarker Data of ipilimumab in Melanoma -- "Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment" (Abstract #3020, Developmental Therapeu...

Ipilimumab in Biological Technology

Medarex Announces 2009 First Quarter Financial Results

...ug conjugates, were also presented at the AACR meeting. Data from clinical trials of investigational oncology products ipilimumab (Phase 2) and MDX-1106 (Phase 1) will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from May ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

... - Updated Survival and Biomarker Data for ipilimumab to be Presented - PRINCETON, N.J., April 29 /...ed today that the following clinical abstracts for ipilimumab in melanoma and prostate cancer, as well as for an... Survival, Response, Safety and Biomarker Data of ipilimumab in Melanoma "Association of ...

BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)

...sly reported efficacy data. Study III (Abstract no. 184) Study title: "Phase I Trial of Targeted Therapy with PSA-TRICOM Vaccine (V) and ipilimumab (ipi) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC)." This NCI conducted study in patients with advanced prost...

Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community

...ancer drugs: the internally developed and recently approved Ixempra (ixabepilone), a new cytotoxic designed to overcome drug resistance; and ipilimumab (MDX-010), a potential new immunotherapy paradigm; -- an internally discovered biologic investigational compound, belatacept, a novel co-s...